Related Experiment Videos
Protein A-immunoadsorption in chemotherapy associated hemolytic-uremic syndrome
E J Borghardt1, E J Kirchertz, I Marten
1Department of Hematology/Oncology (Tumor-Center Hanover), Germany.
Transfusion Science
|February 6, 1998
Summary
Protein A immunoadsorption effectively treats severe cases of hemolytic uremic syndrome (HUS) linked to IgG-immune complexes. This therapy removes harmful IgG and IgG-IC from patient plasma, showing promising results in chemotherapy-induced HUS.
Area of Science:
- Nephrology
- Immunology
- Oncology
Background:
- Circulating IgG-immune complexes (IgG-IC) are implicated in the pathogenesis of atypical hemolytic uremic syndrome (aHUS).
- Severe forms of aHUS can develop following mitomycin-C chemotherapy.
- Identifying effective treatments for chemotherapy-induced aHUS is critical.
Purpose of the Study:
- To evaluate the efficacy of protein A immunoadsorption in treating severe aHUS.
- To assess the removal of IgG and IgG-immune complexes in patients undergoing this treatment.
Main Methods:
- An open clinical study was conducted.
- Protein A immunoadsorption was employed to process large plasma volumes.
- Elimination of IgG and IgG-IC from patient plasma was the primary method.
Main Results:
- Successful treatment was achieved in 14 out of 19 evaluable patients.
- Protein A immunoadsorption demonstrated the capacity to remove IgG and IgG-IC.
- The treatment was applied to patients with severe aHUS post-mitomycin-C chemotherapy.
Conclusions:
- Protein A immunoadsorption is a viable therapeutic option for severe aHUS.
- This method effectively reduces IgG and IgG-IC levels in affected patients.
- Further investigation into this treatment for chemotherapy-induced aHUS is warranted.